Walleye Capital LLC Bei Gene, Ltd. Put Options Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $28,360 - $36,294	200 Added 100.0%	400 $62,000
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $15,866 - $20,158	-100 Reduced 33.33%	200 $36,000
Q3 2023 Nov 21, 2023	BUY	$179.87 - $225.13 $53,961 - $67,539	300 New	300 $53,000
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $588,390 - $880,373	3,300 Added 3300.0%	3,400 $606,000
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $21,553 - $27,450	-100 Reduced 50.0%	100 $21,000
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $25,102 - $45,860	200 New	200 $43,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.